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Objectives: Although Acne vulgaris is a chronic skin disease, which its standard treatment 
causes therapeutic limitations and some common adverse effects, medicinal plants can 
be effective in treatment with low adverse effects as combination therapy. Myrtle (Myrtus 
Communis) has some beneficial properties, which has been administered topically and 
orally for some skin diseases in Persian medicine. This study aimed to compare the effi-
cacy and safety of Myrtle formula and 1% clindamycin topical solution.
Methods: This was a split-face clinical trial that was done on 55 patients with mild to mod-
erate acne vulgaris for 16 weeks. The patients received topical Myrtle solution to the right 
side of the face (group 1) and clindamycin solution to the left side (group 2) twice daily for 
12 weeks. All participants were examined for the acne severity index (ASI) and total acne 
lesions counting (TLC) at certain times during the study. Then, they stopped using them for 
four weeks. They also did not take the drug in the final four weeks of the study.
Results: Forty-eight patients completed the study for 16 weeks; 40 (83.2%) patients were 
female and the rest of them were male. The mean age and standard deviation were 25.62 
± 7.62 years. After 12 weeks, the percentage changes of comedones, inflammatory le-
sions, ASI and TLC were significantly reduced in both groups (p < 0.001). The percentage 
change of inflammatory lesions and ASI decrease was significantly higher in the group 1 (p 
= 0.03). There was no significant difference in the incidence of side effects between the 
two groups. There was a more significant decrease in sebum percentage change in the 
group 1 (p = 0.003).
Conclusion: Myrtle lotion was effective and safe for the treatment of mild to moderate 
acne vulgaris. 
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Acne Vulgaris is a chronic inflammatory disease of the seba-
ceous glands, which is one of the most prevalent skin diseases 
among adolescents and young people worldwide. Its prevalence 
varies between countries and ethnic groups and it is estimated 
to be from 35 to over 90 percent [1, 2]. Clinical types of acne 
include non-inflammatory lesions (e.g, sebum, black and white 
comedones) and inflammatory lesions (e.g, papules, pustules, 
and nodules) [3]. In mild and moderate acne vulgaris, topi-
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cal drugs are most commonly used [4]. A number of patients, 
discountinue topical treatments owing to unresponsiveness 
and side effects such as irritation, erythema, scaling, itching, 
and stinging, which consequently, lead to treatment failure [5]. 
Therefore, consumption of natural remedies has been consid-
ered, it is believed that they are the safe source for finding new 
biologically active treatment and have low side effects as well. A 
variety of medicinal herbs are used orally, topical or together for 
acne treatment worldwide [6, 7]. Myrtle (Myrtus Communis) 
is herbal medicine and its topical and oral use has been recom-
mended for some kinds of skin diseases in Persian medicine [8]. 
Myrtle shows antiproliferative, antibacterial, and antiinflamma-
tory properties in different in-vitro and in-vivo studies [9, 10]. 
A clinical study indicated that Myrtle essential oil had antibac-
terial activity and also valuable effects on removal of sebum and 
dead skin cells, and reduction in erythema [11]. 
The present study was conducted to assess the effect of topi-
cal Myrtle solution compared to clindamycin 1% solution on 
decreasing mild to moderate acne lesions.
MATERIAL AND METHODS
This study was a triple blind, non-randomized, split-face 
clinical trial. All the patients were recruited from three univer-
sity centers in Tehran, Iran, from June 2017 to April 2019. The 
inclusion criteria were both the men and women, aged between 
12 to 45 years old, with mild to moderate acne vulgaris on their 
faces. The characteristics of the lesions also include TLC score: 
20-140, non-inflammatory lesions: 10-50, inflammatory le-
sions: 10-50, and lack of sinus tract, cysts, and nodules. Patients 
were excluded if they had a contemporary skin disease such as 
scar, rosacea, psoriasis that interfere with the assessment of acne 
lesions, acute systemic diseases, pregnancy, breast-feeding, the 
consumption of local treatment of acne in two months before 
or during the study, taking oral retinoic acid in six months be-
fore the study, and allergy to the drugs or their compounds.
The Ethics Committee of Iran University of Medical Sci-
ences approved this study (Ethics code: IR. IUMS FMD.REC 
1396.9321309010). Informed consent was taken from each 
participant. The study was registered in the Iranian Registry of 
Clinical Trials (registration no. IRCT 20171122037581N1).
1. Plant material and drug preparation
The required amount of Myrtle dried leaves were purchased 
from the herbal market in Tehran, Iran. The herbarium code 
of PMP-447 was obtained from the botany lab and herbarium 
of faculty of pharmacy, Tehran University of Medical Sciences, 
Tehran, Iran. The plant leaves were ground to powder using an 
electric miller. The ethanolic extract of Myrtle was prepared by 
maceration method using ethanol/water solvent. For this rea-
son, 100 g of grounded powder was macerated with 500 mL of 
EtOH: H2O (80:20) for 48 h. 
2. Sample size 
To estimate the sample size, data were derived from a pilot 
study of 10 subjects. It was calculated using the comparison of 
the formula for the means between matched pairs groups, on 
the basis of following assumptions: α = 0.05, p = 80%, effect 
size = 0.6 and the attrition rate of 20%, the sample size was cal-
culated to be 55 patients. 
3. Study design and population
Fifty-five patients who met the inclusion criteria were en-
rolled in this study. They received topical Myrtle solution on 
the right side and clindamycin 1% solution on the left side of 
their faces twice daily for 12 weeks. After completing active 
therapy, the patients were drug-free for four weeks to follow up. 
During the study, the patients, the researchers and the statistical 
analyzer were unaware of the contents of the treatment.
The Myrtle and clindamycin 1% solution were administered 
for each patient in two opaque containers, both drugs are the 
same in their shapes and odors. Patients were visited and the 
treatment sites evaluated at the beginning of the study and then 
after 6, 12 and 16 weeks.
In each visit, the number of inflammatory and non-inflam-
matory lesions, ASI and TLC were evaluated. ASI and TLC 
were calculated by the following formula [12]:
Total lesion count (TLC) =  papules + pustules + comedones + 
nodules 
Acne Severity Index (ASI) =  papules + (pustules × 2) +  
(comedones / 4) + (nodules × 3) 
At each visit adverse events (AEs) including erythema, burn-
ing, itching, dryness, scabbing, aggravation of lesion and edema 
were assessed through direct questions and clinical assessment 
by the investigator. The numeric rating scale represents 0 = 
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none, 1 = mild, 2 = moderate and 3 = severe.
The following skin biophysical characteristics were mea-
sured on both sides of the face at the baseline and the end of the 
study on 16th week: Fluorescence photography was conducted 
usingVisiopor® PP 34 camera (Courage-Khazaka, Germany) 
with narrow-band UVA light (375 nm) and image size of 6.4 × 
8 mm. Photographs were taken from the left and right cheek. 
The number of orange-red fluorescence spots were assessed. 
The orange-red fluorescence indicates the presence of Propioni-
bacterium acne (P. acne) within clinically non-evident (follicular 
impactions and microcomedones) and clinically evident le-
sions (comedones, papules and pustules). Four skin biophysical 
characteristics were measured using MPA-9 (Courage-Khazaka, 
Germany). The erythema index and melanin index were mea-
sured using Mexameter MX 18. Stratum corneum hydration 
and sebum content, were measured by Corneometer CM 825, 
Sebumeter SM 815, respectively. All measurements were per-
formed on the left and right cheek in a room at 20-25℃ tem-
perature and a relative humidity of treatment. 
4. Endpoints
The efficacy end point was the comparison of the inflamma-
tory, non-inflammatory, TLC and ASI and percent change of 
them at baseline and week 12. Patient’s satisfaction was scored 
from 0-4 (i.e. 0 = worse, 1 = no response, 2 = poor response, 3 = 
good response, 4 = excellent). 50% recovery was compared on 
both sides; drugs safety was measured through evaluating side-
effects. The evaluation of side effects was based on “common 
terminology criteria for adverse events V4. 0 2009”.
5. Statistical analysis
Data were analyzed using SPSS software (SPSS Inc. Version 
17.0. Chicago, IL, USA). Variables were described by the mean, 
standard deviation. Normal distribution of variables was evalu-
ated using Kolmogorov-Smirnov and Shapiro-Wilk tests. Fried-
man’s test was used to determine the changes in the variables 
during the study. Wilcoxon matched-pairs signed ranks test was 
used to compare the variables between the right and left side of 
the face and pairwise comparisons on each side. The qualitative 
variables were compared between two sides of the face using 




A total of 83 individuals with mild to moderate acne vulgaris 
were interviewed in 3 university centers of whom, 55 subjects 
were enrolled to the study. These patients referred to one cen-












Comedones 1 24 (15.11) 19.22 (16.2) 17.58 (14.08) < 0.001 17.06 (10.54) < 0.001
2 23.66 (12.71) 19.68 (14.56) 18.58 (14.49) 0.002 20.33 (13.94) 0.002
p value** 1 0.54 0.27 0.016
Inflammatory 
   lesions
1 10.10 (7.10) 5.2 (4.7) 4 (3.82) < 0.001 4.2 (3.38) < 0.001
2 8.16 (6.05) 5.77 (5.14) 4.58 (4.59) < 0.001 4.72 (3.97) < 0.001
p value 0.004 0.56 0.35 0.10
TLC 1 34.1 (17.48) 24.43 (18.24) 21.58 (15.65) < 0.001 21.27 (11.45) < 0.001
2 31.83 (13.04) 25.45 (14.65) 23.16 (14.93) < 0.001 25.06 (14.76) < 0.001
p value** 0.28 0.31 0.07 0.01
ASI 1 18.33 (9.6) 11.24 (8.6) 9.16 (6.67) < 0.001 9.34 (5.03) < 0.001
2 15.77 (8) 11.88 (7.35) 10.39 (7.44) < 0.001 11.02 (6.48) < 0.001
p value** 0.02 0.3 0.21 0.02
Formulation 1 = Myrtus Communis, Formulation 2 = clindamycin 1%. SD, standard deviation; TLC, total lesion count; ASI, acne severity index. 
*Friedman Test, **Wilcoxon matched pairs signed ranks test. 
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ter. Clinical examinations and skin biophysical characteristic 
measurements were performed by one person. The study began 
with a total of 55 patients and seven persons dropped-out the 
study. Finally, 48 patients completed the study during 16 weeks. 
Forty subjects (83.2%) were female and the rest of them were 
male. The mean age and standard deviation were 25.62 ± 7.62 
years.
At baseline, there were no significant differences among the 
subjects in terms of the mean TLC (p = 0.28) and comedone 
score (p = 1), but the mean number of inflammatory lesions (p 
= 0.004) and ASI (p = 0.02) was significantly higher on the right 
side compared to the left ones. Table 1 presents a comparison of 
the skin lesions, TLC, ASI and their changes in two sides.
Fig. 1 presents percent changes in comedones, inflammatory 
lesions, TLC and ASI at 16th week compared to the baseline.
2. Efficacy on total lesion scores (TLC)
At the beginning of the study, the mean scores of TLC on 
the right and left sides of the face were 34.1 ± 17.48 and 31.83 ± 
13.04, respectively (Table 1). There was no significant difference 
between two sides in terms of decrease in the mean TLC in the 
6 and 12 weeks (p = 0.31 and p = 0.07, respectively). In the 16th 
week, the subjects were reported increased TLC on both sides 
of the face compared to the 12th week of the study, however, 
percentage changes were significantly higher on the right side 
(p = 0.01). In both sides there was a significant decrease in TLC 
at the 12th and 16th weeks. Percentage change in TLC showed 
no significant difference at 12th week compared to baseline be-
tween the two sides (p = 0.1).
3. Efficacy on non-inflammatory lesion (comedone) scores
In the 6th and 12th weeks of the study, the number of comedo-
nes were significantly decreased on both sides compared to the 
baseline (p < 0.001). In the 12th week, there was no significant 
difference in percentage changes of comedones between the two 
sides compared to the baseline (p = 0.64). In the 16th week, the 
mean number of comedones was higher on the left side (p = 0.01).
4. Efficacy on inflammatory lesion scores
At baseline, the mean number of inflammatory lesions was 
significantly higher on the right side (p = 0.004). In the 12th 
week, there was a significant decrease in the mean number of 
inflammatory lesions on both sides (p < 0.001), but on the right 
side, the inflammatory lesion percentage was significantly de-
creased more than the left side (p = 0.03).
5. Efficacy on acne severity index (ASI)
ASI was significantly higher on the right side compared to 
the left side at baseline conditions (p = 0.02). In the 6th and 12th 
weeks, the decreasing of ASI was equal on both sides (p < 0.001). 
The significant change in ASI seems obscure. Thus, it is neces-
sary to compare the percentage changes of ASI in both sides in 
order to properly explain the results. After 12 weeks, there was 
a significant decrease in ASI percentage change for both sides 
compared to the baseline, but ASI percentage decrease on the 
right side was significantly higher (p = 0.03).
The percent changes of TLC and ASI in the 6th and 12th 
weeks are shown in Table 2.
6. Skin biophysical characteristics
There was a significant difference in melanin levels between 
the two sides at baseline (p = 0.04), and their percentage chang-
es were not significant after 16 weeks (p = 0.49).
At 16th week, there was a significant increase in moisture 
level with clindamycin, while it was decreased with Myrtle, 
nevertheless, there was no significant difference in percentage 
change (p = 0.07).
After 16 weeks, sebum level was significantly lower with 
Myrtle (p = 0.009). Also, the percentage decrease with Myrtle 
was significantly higher than clindamycin (p = 0.003). 
Erythema increased on the side treated with Myrtle, how-
Figure 1. Percent changes in comedones, inflammatory cells, TLC and 
ASI at 16 weeks compared to baseline; 1 = Myrtus Communis, 2 = 
clindamycin. 
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ever, it decreased with clindamycin at 16th week, which the 
difference was significant (p = 0.02). However, the percentage 
changes of erythema between both formulations were not sig-
nificant (p = 0.46).
The percentage changes of P. acne (Visiopor) decreased for 
both products, but their differences were not statistically sig-
nificant (p = 0.8). Table 3 demonstrates skin biophysical charac-
teristics in the study population.
7. Recovery
The recovery was considered a 50% decrease in ASI at 6th 
and 12th weeks. It was observed at 6th week with Myrtle in 22 
patients (45.8%) and with clindamycin in 13 patients (27.1%), 






Comedones percent change 1 21.55 (40.02) –25.96 (74.54)
2 13.21 (59.15) –43.33 (102.09)
p value 0.64 0.39
Inflammatory lesions percent change 1 52.36 (50.30) –41.94 (131.25)
2 41.80 (48.03) –24.86 (98.06)
p value 0.03 0.56
TLC percent change 1 34.13 (34.51) –23.74 (63.49)
2 26.47 (34.80) –27.96 (072.40
p value 0.1 0.69
ASI percent change 1 45.08 (38.97) –39.14 (94.87)
2 34.15 (33.93) –32.51 (93.87)
p value 0.03 0.71
Formulation 1 = Myrtus Communis, Formulation 2 = clindamycin 1%. SD, standard deviation.









Melanin 1 197.01 (40.82) 199.70 (43.03) 0.5 –2.29 (14.56)
2 206.83 (53.15) 202.69 (38.20) 0.95 –0.19 (13.63)
p value* 0.04 0.4 0.49
Skin moisture 1 37.47 (11.38) 33.82 (12.67) 0.04 5.53 (36.49)
2 37.47 (11.38) 37.61 (12.85) 0.69 –7.46 (49.99)
p value* 1 0.03 0.07
Sebum (μg/cm2) 1 87.85 (58.89) 73.42 (47.30) 0.02 1.18 (64.22)
2 87.85 (58.89) 82.61 (49.14) 0.58 –15.13 (77.55)
p value* 1 0.009 0.003
Erythema 1 387.89 (72.22) 392.63 (91.22) 0.44 –2.21 (20.07)
2 377.06 (74.06) 376.34 (80.68) 0.66 –0.84 (16.48)
p value* 0.16 0.02 0.46
P. acne count 1 18.58 (13.02) 16.06 (11.81) 0.02 6.74 (59.10)
2 17.52 (13.40) 14.39 (11.09) 0.01 11.20 (57.11)
p value* 0.16 0.11 0.82
Formulation 1 = Myrtus Communis, Formulation 2 = clindamycin 1%. SD, standard deviation.
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which was significantly higher for Myrtle (p = 0.04), but at 12th 
week, the rate of recovery was not significantly different be-
tween both sides of the face (p = 0.14).
8. Adverse events
Table 4 shows the number of patients experiencing any AEs. 
Eighteen patients (37.6%) with Myrtle and 21 subjects (43.8%) 
with clindamycin reported at least one AEs after six weeks. It 
was decreased to 13 patients (26.2%) for Myrtle and 19 subjects 
(39.7%) for clindamycin at 12th week. The severity of symptoms 
on both sides of the face were mild to moderate, and none of 
them was severe. Scabbing, was the most common AEs for both 
Myrtle and clindamycin at the 6th and 12th weeks with no signif-
icant difference (p = 1 and p = 0.65, respectively). The second 
common AEs for both products were an aggregation of lesion (p 
= 0.73) in the 6th week and dryness (p = 0.08) in the 12th week. 
The results showed no significant difference in the incidence 
of side effects between the two formulations.
9. Patient’s satisfaction
The participants reported satisfaction with treatment as fol-
lows: median interquartile range (IQR) was between 3 (2-3.75) 
and 2 (2-3) for Myrtle and clindamycin respectively. The satis-
faction was significantly higher for Myrtle (p = 0.02). 
10. Recurrence 
In both formulations, the percent changes of TLC, ASI, in-
flammatory and non-inflammatory lesion were increased at 
16th week compared to 12th week. The recurrence rate was not 
significantly different between them (Table 2).
Fig. 2 and 3 show photograph of one subject who received 
the Myrtle (right side of the face) and clindamycin (left side of 
the face) in the baseline and end of the study (at 16th week).
DISCUSSION
The aim of this split-face study was to compare the efficacy 
and safety of Myrtle and clindamycin solution in patients with 
mild to moderate acne vulgaris on their faces. In this study, the 
decrease in the inflammatory and non-inflammatory lesions, 
ASI and TLC percentage changes were significant on both sides 
of the face at 12th week. There was a significant difference in the 
reduction of inflammatory lesions and ASI percentage changes 
for Myrtle compared to clindamycin. The significant decrease 
of sebum, as a precursor of acne, was one of the most out-
standing features of Myrtle lotion. The patient’s satisfaction for 
Myrtle was significantly higher than the clindamycin and the 
incidences of AEs between both formulations were similar.
Acne vulgaris is a multifactorial skin disease and some of 
its aspects remain unknown yet. Four key factors have been 
identified in the pathogenesis of acne, including increased se-
bum production, follicular hyperkeratinization, colonization of 
the pilosebaceouse unit with P. acnes and in flammation [13]. 
Its medical treatment is based on the effect of one or several 
factors to prevent the development of the lesion by inhibiting 
sebum growth, normalizing follicular hyperkeratinization, de-
creasing P. acnes colonization and inhibition of inflammation 
[14]. Releasing free radicals and inflammatory mediators reflect 
the presence of oxidative stress state in parts of the pathogenesis 
of acne, therefore, the use of antioxidant and anti-inflammatory 
agents has been considered along with usual medication for the 













Scabbing 10 (20.8%) 9 (18.8%) 1 7 (13.6%) 8 (16.7%) 0.65
Dryness 3 (6.3%) 4 (8.3%) 0.65 3 (6.3%) 5 (10.4%) 0.08
Aggregation 4 (8.4%) 5 (10.4%) 0.73 2 (4.2%) 1 (2.1%) 0.56
Burning 1 (2.1%) 2 (4.2%) 0.31 0 (0%) 1 (2.1%) 0.31
Itching 0 (0%) 1 (2.1%) 0.31 1 (2.1%) 2 (4.2%) 0.31
Edema 0 (0%) 0 (0%) 1 0 (0%) 1 (2.1%) 0.31
Erythema 0 (0%) 0 (0%) 1 0 (0%) 1 (2.1%) 0.31
AE, adverse event.
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treatment of acne vulgaris [15]. 
It is believed that increased production of keratinocytes and 
subsequent retention can be considered a comedogenic factor 
[16]. An in vitro study conducted on ethanol product of Myrtle 
leaves (Myrtacin) have demonstrated anti-proliferative activi-
ties on human keratinocytes. Myrtacin inhibits keratinocyte 
proliferation by 27% and 76% at 1 and 3 μg/mL, respectively. 
The effective antiproliferative compounds of Myrtacine were 
Myrtucommulone A and B [9].
Colonization of the pilosebaceouse unit with Staphylococ-
cus aureus, Staphylococcus epidermidis and P. acnes is another 
key factor in the pathogenesis of acne [17]. Myrtle has strong 
antimicrobial activity because of high content of monoterpene 
hydrocarbons such as α-pinene, limonene, linalool, eucalyptol 
and terpineol [18-20].
An in vitro study showed active compounds of Myrtle inhib-
ited P. acnes growth. Three compounds, including 5-acetoxy-
4-hydroxy-4-isobutyl 2, 2, 6, 6-tetramethylcyclohexan-1,3-
dione and isomyrtucommulone-B demonstrated the highest 
antibacterial effect and strong inhibition against P. acnes [21].
The bactericidal activity of the ethanol product of Myrtle 
leaves (Myrtacin) and myrtucommulone A and B against eryth-
romycin-sensible and resistant P. acnes strains was determined 
by measuring the MIC and D value. The extracts inhibited P. 
acnes strains growth with MICs of 4.9 μg/mL and 2.4 μg/mL, 
respectively. Myrtucommulone A and B also showed inhibitory 
activity against both strains (MICs of 1.2 μg/mL and about 0.5 
μg/mL, respectively). The extract also exhibited a concentra-
tion-dependent antilipase activity [9]. P. acnes produces lipases, 
proteases, and hydrolases, contributing to inflammation [22].
Figure 2. Photographs of one subject, right and left half the face before treatment.
Figure 3. Photographs of one subject in myrtle (right half the face) and clindamycin (left side of the face) after treatment (16th weeks).
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Several studies showed anti-inflammatory properties of es-
sential oil, aqueous and ethanolic extract of Myrtle in animal 
model [23]. Anti-inflammatory effect of Myrtle also related to 
the Myrtucommulone (MC) and a lesser extent of Semi-Myr-
tucommulone (S-MC) and nonprenylated acylphloroglucinols. 
This is due to their ability to suppress the biosynthesis of eico-
sanoids by direct inhibiting cyclooxygenase-1 and 5-lipoxygen-
ase in vitro and in vivo. They also have a restraining effect on 
synthesis of ROS species and release of elastase as the initiating 
factor of inflammation [24].
Releasing free radicals and inflammatory mediators reflect 
the presence of oxidative stress state in parts of the pathogenesis 
of acne, Oxidative stress is initiated by reactive oxygen species 
(ROS). Three free radicals (hydroxyl, superoxide and nitrous 
oxide) are responsible for the occurrence of irritation during 
the acne infection; therefore, the use of antioxidant and anti-
inflammatory agents has been considered along with usual 
medication on the treatment of acne vulgaris [15, 25, 26]. Anti-
oxidant activity and total phenolic compounds of four extracts 
(water, methanol, ethanol, and ethyl acetate) of Myrtus commu-
nis were measured. The methanol and water extracts possess 
significant antioxidant activities. This order is observed in both 
leaf and berry extracts. They showed that it is a rich source of 
phenolic content, which has been reported as an active antioxi-
dant component. There is also a linear correlation between the 
phenolic content and antioxidant activity [27-29]. 
Clinical studies have also been performed to evaluate the ef-
fect of different topical Myrtle products in patients with acne, 
which confirm the results of in vitro and in vivo studies. 
A prospective, randomized, parallel-group study was con-
ducted on 164 patients with mild to moderate acne, who previ-
ously developed a retinoid dermatitis, in which, one group of 
patients received 0.2% Myrtacine and 4% nicotinamide, and the 
second group treated with a moisturizer. Patients treated with 
the Myrtacine / nicotinamide combination showed a statistical-
ly significant improvement in symptoms (pruritus, stinging and 
burning sensation) and signs (erythema, dryness and oedema). 
This good result also observed in patient with nodular acne [30]. 
A clinical study was performed with products containing 
Myrtacine on erythromycin-resistant strains of cutibacterium. 
acnes. Sixty patients with global acne severity evaluation (GEA) 
scale who had GEA grades 2 and 3 acne were treated with 
Myrtacine-based dermocosmetic twice daily for 8 weeks. At 
baseline, antibiotic-resistant strains of cutibacterium. acnes 
were detected in 38 patients. Global cutibacterium. acnes popu-
lation counts were stable at the end of the study, however, there 
was a significant reduction of erythromycin-resistant strains of 
cutibacterium. acne. There was also a significant reduction of 
inflammatory and non-inflammatory lesions and acne severity 
after 8 weeks [31].
In another study on 20 Korean women with acne vulgaris 
for 6 weeks, it is clinically proved Myrtle essential oil has ben-
eficial effects. The acne grades significantly decreased in the 
Myrtle group. The pore index, the erythema index, the sebum 
index, microorganism index and the desquamation index also 
decreased in the group in a statistically significant manner. In 
the control group with no Myrtle, the acne grades and the mi-
croorganism index a little decreased, but was not statistically 
significant, while the pore, erythema, sebum and desquamation 
indices rather increased to some extent [11].
Our results are consistent with those of those previous clini-
cal trials on Myrtle products. In our study, erythema index 
was not reduced, which differed from the latest study findings. 
This difference may be related to the duration of the study (12 
weeks versus 6 weeks) and the type of Myrtle product (ethanolic 
extract versus essential oil). We believe our study duration was 
more appropriate. One of the common findings between our 
study and the latest study is a decrease in sebum index. The 
number of P. acne that measured by Visiopor showed a signifi-
cant decrease in our study. The effectiveness of Myrtle formula 
was significant on the assessment of ASI, TLC, inflammatory 
and non-inflammatory lesion. No withdrawals owing to adverse 
effect of Myrtle were reported in our trial. The efficacy and 
good tolerance of Myrtle formula demonstrated in our study 
were consistent with the results of previous studies.
The small sample size was the main limitation of this study. 
Other studies with larger sample size and higher dosage of Myr-
tle can be designed to investigate its effects on acne treatment.
CONCLUSION
This study showed a significant decrease in the inflamma-
tory and non-inflammatory lesions, ASI and TLC percentage 
changes on both sides of the face at 12th week. There was a sig-
nificant difference in the reduction of inflammatory lesions and 
ASI percentage changes for Myrtle compared to clindamycin. 
The results showed that Myrtle is as effective as clindamycin 
in treating mild to moderate acne. The significant decrease of 
sebum, as a precursor of acne, was one of the most outstanding 
features of Myrtle lotion. The patient’s satisfaction for Myrtle 
228 https://doi.org/10.3831/KPI.2020.23.4.220
Mahboobeh Salmanian, et al.
was significantly higher than the clindamycin and the incidenc-
es of AEs between both formulations were similar. 
Myrtle can be used as a natural drug beside other standard 
topical drug in the treatment of acne vulgaris to improve clini-
cal efficiency and reduce possible side effects.
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